A systematic review of gut microbiota profile in COVID-19 patients and among those who have recovered from COVID-19.


Journal

Journal of digestive diseases
ISSN: 1751-2980
Titre abrégé: J Dig Dis
Pays: Australia
ID NLM: 101302699

Informations de publication

Date de publication:
Apr 2023
Historique:
revised: 04 04 2023
received: 04 01 2023
accepted: 30 05 2023
medline: 17 7 2023
pubmed: 2 6 2023
entrez: 2 6 2023
Statut: ppublish

Résumé

Given the scale and persistence of coronavirus disease 2019 (COVID-19), significant attention has been devoted to understanding the relationship between human gut microbiota and COVID-19. In this systematic review we aimed to comprehensively assess the gut microbiota composition in patients infected with COVID-19 and those recovered from COVID-19 in comparison to healthy controls (HCs). Peer-reviewed articles and preprints published up to September 1, 2022, were searched in Ovid MEDLINE, Ovid EMBASE, and SCOPUS. Observational studies reporting the gut microbiota profile in adult (≥18 years) COVID-19 patients or those recovered from COVID-19 compared to HCs were eligible for inclusion in this systematic review. The quality assessment of studies was performed using the Newcastle-Ottawa scale. We identified 27 studies comprising 18 studies that compared COVID-19 patients and six that compared recovered COVID-19 patients to HCs, while the other three studies compared both COVID-19 and recovered COVID-19 patients to HCs. Compared to HCs, decreased gut microbial diversity and richness and a distinctive microbial composition were reported in COVID-19 patients and recovered COVID-19 patients. In COVID-19 patients, Bacteroidetes were found to be enriched, and Firmicutes depleted. Decreased short-chain fatty acid (SCFA)-producing bacteria, such as Faecalibacterium, Ruminococcus, and Bifidobacterium, among others, were also observed in COVID-19 patients, which were not restored to normal levels in those who recovered. Gut dysbiosis was evident in COVID-19, and available data suggested that dysbiosis persisted even in recovered COVID-19 patients, with decreased Firmicutes and SCFA-producing bacteria.

Identifiants

pubmed: 37265376
doi: 10.1111/1751-2980.13195
doi:

Substances chimiques

Fatty Acids, Volatile 0

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-261

Informations de copyright

© 2023 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Références

Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219-232.
Pu QQ, Lin P, Gao P, et al. Gut microbiota regulate gut-lung axis inflammatory responses by mediating ILC2 compartmental migration. J Immunol. 2021;207(1):257-267.
Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID-19: a systematic review. PLoS One. 2021;16(6):e0253293. doi:10.1371/journal.pone.0253293
Woodall CA, McGeoch LJ, Hay AD, Hammond A. Respiratory tract infections and gut microbiome modifications: a systematic review. PLoS One. 2022;17(1):e0262057. doi:10.1371/journal.pone.0262057
Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi:10.1371/journal.pmed.1003773
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
Gu SL, Chen YF, Wu ZJ, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669-2678.
Tao WY, Zhang GR, Wang XF, et al. Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Med Microecol. 2020;5:100023. doi:10.1016/j.medmic.2020.100023
Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955.e8.
Al Bataineh MT, Henschel A, Mousa M, et al. Gut microbiota interplay with COVID-19 reveals links to host lipid metabolism among Middle Eastern populations. Front Microbiol. 2021;12:761067. doi:10.3389/fmicb.2021.761067
Gaibani P, D'Amico F, Bartoletti M, et al. The gut microbiota of critically ill patients with COVID-19. Front Cell Infect Microbiol. 2021;11:670424. doi:10.3389/fcimb.2021.670424
Khan M, Mathew BJ, Gupta P, et al. Gut dysbiosis and IL-21 response in patients with severe COVID-19. Microorganisms. 2021;9(6):1292. doi:10.3390/microorganisms9061292
Li SJ, Yang SY, Zhou YZ, et al. Microbiome profiling using shotgun metagenomic sequencing identified unique microorganisms in COVID-19 patients with altered gut microbiota. Front Microbiol. 2021;12:712081. doi:10.3389/fmicb.2021.712081
Liu YJ, Zhang HY, Tang XJ, et al. Distinct metagenomic signatures in the SARS-CoV-2 infection. Front Cell Infect Microbiol. 2021;11:706970. doi:10.3389/fcimb.2021.706970
Wu CY, Xu Q, Cao Z, et al. The volatile and heterogeneous gut microbiota shifts of COVID-19 patients over the course of a probiotics-assisted therapy. Clin Transl Med. 2021;11(12):e643. doi:10.1002/ctm2.643
Wu YJ, Cheng XM, Jiang GM, et al. Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization. NPJ Biofilms Microbiomes. 2021;7(1):61. doi:10.1038/s41522-021-00232-5
Rafiqul Islam SM, Foysal MJ, Hoque MN, et al. Dysbiosis of oral and gut microbiomes in SARS-CoV-2 infected patients in Bangladesh: elucidating the role of opportunistic gut microbes. Front Med (Lausanne). 2022;9:821777. doi:10.3389/fmed.2022.821777
Zhang F, Wan YT, Zuo T, et al. Prolonged impairment of short-chain fatty acid and l-isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162(2):548-561.e4.
Zhou TY, Wu JY, Zeng YF, et al. SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota. MedComm (2020). 2022;3(1):e112. doi:10.1002/mco2.112
Hazan S, Stollman N, Bozkurt HS, et al. Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. BMJ Open Gastroenterol. 2022;9(1):e000871. doi:10.1136/bmjgast-2022-000871
Mizutani T, Ishizaka A, Koga M, et al. Correlation analysis between gut microbiota alterations and the cytokine response in patients with coronavirus disease during hospitalization. Microbiol Spectr. 2022;10(2):e0168921. doi:10.1128/spectrum.01689-21
Sehli S, Idrissi Azami A, Dini N, et al. Gut microbiome 16S rRNA gene amplicon taxonomic profiling of hospitalized Moroccan COVID-19 patients. Microbiol Resour Announc. 2022;11(7):e0025622. doi:10.1128/mra.00256-22
Shen YF, Yu F, Zhang D, et al. Dynamic alterations in the respiratory tract microbiota of patients with COVID-19 and its association with microbiota in the gut. Adv Sci (Weinh). 2022;9(27):e2200956. doi:10.1002/advs.202200956
Xu XG, Zhang W, Guo MQ, et al. Integrated analysis of gut microbiome and host immune responses in COVID-19. Front Med. 2022;16(2):263-275.
Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-552.
Tian Y, Sun KY, Meng TQ, et al. Gut microbiota may not be fully restored in recovered COVID-19 patients after 3-month recovery. Front Nutr. 2021;8:638825. doi:10.3389/fnut.2021.638825
Zhou YY, Zhang JC, Zhang DM, Ma WL, Wang XR. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. J Microbiol. 2021;59(10):941-948.
Chen YF, Gu SL, Chen YB, et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71(1):222-225.
Cui GY, Rao BC, Zeng ZH, et al. Characterization of oral and gut microbiome and plasma metabolomics in COVID-19 patients after 1-year follow-up. Mil Med Res. 2022;9(1):32. doi:10.1186/s40779-022-00387-y
Ferreira-Junior AS, Borgonovi TF, De Salis LVV, et al. Detection of intestinal dysbiosis in post-COVID-19 patients one to eight months after acute disease resolution. Int J Environ Res Public Health. 2022;19(16):10189. doi:10.3390/ijerph191610189
Yeoh YK, Zuo T, Lui GCY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706.
Schult D, Reitmeier S, Koyumdzhieva P, et al. Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. Gut Microbes. 2022;14(1):2031840. doi:10.1080/19490976.2022.2031840
Maeda Y, Motooka D, Kawasaki T, et al. Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity. BMC Infect Dis. 2022;22(1):572. doi:10.1186/s12879-022-07358-7
Yao Y, Cai XY, Fei WD, Ye YQ, Zhao MD, Zheng CH. The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit Rev Food Sci Nutr. 2022;62(1):1-12.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.
Zhang DP, Li S, Wang N, Tan HY, Zhang ZM, Feng YB. The cross-talk between gut microbiota and lungs in common lung diseases. Front Microbiol. 2020;11:301. doi:10.3389/fmicb.2020.00301
Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016;1(10):16113. doi:10.1038/nmicrobiol.2016.113
McAleer JP, Kolls JK. Contributions of the intestinal microbiome in lung immunity. Eur J Immunol. 2018;48(1):39-49.
Moreira-Rosário A, Marques C, Pinheiro H, et al. Gut microbiota diversity and C-reactive protein are predictors of disease severity in COVID-19 patients. Front Microbiol. 2021;12:705020. doi:10.3389/fmicb.2021.705020
Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-16736.
Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00277
Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979. doi:10.3389/fmicb.2016.00979
Haak BW, Littmann ER, Chaubard JL, et al. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood. 2018;131(26):2978-2986.
Oliva A, Miele MC, Di Timoteo F, et al. Persistent systemic microbial translocation and intestinal damage during coronavirus disease-19. Front Immunol. 2021;12:708149. doi:10.3389/fimmu.2021.708149
Bernard-Raichon L, Venzon M, Klein J, et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat Commun. 2022;13(1):5926. doi:10.1038/s41467-022-33395-6
Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. doi:10.1080/19490976.2021.2018899

Auteurs

Daniel Martin Simadibrata (DM)

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Elvira Lesmana (E)

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Jeffri Gunawan (J)

Department of Internal Medicine and Diagnostics, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia.

Eamonn Martin Quigley (EM)

Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas, USA.

Marcellus Simadibrata (M)

Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Ciptomangunkusumo Hospital, Jakarta, Indonesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH